The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Still ticking up .encouraging to see how azn keeps moving up .For interests those at bsfa remember price there today and look in a few months and see if a high percentage move up . azn one my hopes for this year .
Grayling in my opinion azn was a good investment .For a growing percentage of the World climate change is a partly a hoax . https://www.geoengineeringwatch.org Millions are now watching this .So many are now concerned at the risk of damage to their health . More people are now looking up at the sky above their house for Chemtrails on a day with clear skys .Personly want to see azn share price keep moving up .
Pop !!
Nice short & a way to go.
Mate I was given these ! I have 300 shares given by my dad who worked for ICI FIBRES ! He has a shed load ! All I mentioned was market manipulation and out came Grayling thinking I was a conspiracy theorist
fine confluence, why do you ask ?!
Just like Grayling, I bought in at around 33 pounds, and have always held, apart from the odd dips, when they were around 80pounds, when I bought and sold. It seems to me that some of these posts are pure green eye…..
You missed a great investment, and cannot afford to buy in now!
Oh jog on ! Grayling !
Simples if more people want to sell than want to buy it drops and vice versa it rises! Conspiracy theorists cannot accept this fact as they are t**ts
Grayling ! Explain the drop yesterday and the swing up this morning ! Clever Clogs -:))
Probably nobody. Anyone with half a brain has been invested for years. As for “market manipulation” you probably think that Covid19 was a hoax, climate change does not exist and Trump is god. LOL
Who got sucked in at the top this morning ? Market manipulation at its best !!
@Noveck, are you ok?
Now my most valuable holding. Bought at £30 the gift that keeps on giving and now bigger than upstart Pfizer. In Pascal we trust. LOL
Really..
Sound company. Slight dip in revenue but hopefully already priced in to SP.
Looks positive to me, yes total revenue is down slightly but the 15% increase in non covid revenue is very nice
Financial performance (Q1 2023 figures unless otherwise stated, growth numbers at CER)
? Total Revenue stable at $10,879m, despite a decline of $1,460m from COVID-19 medicines
? Excluding COVID-19 medicines, Total Revenue increased 15% and Product Sales increased 16%
? Total Revenue from Oncology medicines increased 19%, CVRM7 22%, R&I8 8%, and Rare Disease 14%
? Core Gross margin of 83%, up four percentage points, reflecting the decline in sales of lower margin COVID-19 medicines, the cost of production in prior periods, and a mix shift to more speciality medicines
? Core Operating margin of 36%, up one percentage point, reflecting a $220m increase in Core Other operating income, which included a gain from the divestment of Pulmicort Flexhaler rights in the US
? Core EPS increased 6% to $1.92
? Reiterating guidance for FY 2023 Total Revenue and Core EPS
https://www.astrazeneca.com/media-centre/press-releases/2023/q1-2023-results.html
.
All I am suggesting is that in the next 5 years we will probably get 3% pa in dividend and maybe 10-15% in capital gain……I certainly would not expect another 75% capital gain (which is adding £135bn and take the mcap to well over £300bn.
This is not a highly scaleable tech company……its products are highly regulated for quality, target market and price and it takes £1bn or more to bring a new drug to market….
This is most definitely a capital growth stock for me. Only been investing in AZN since 2019. It's my second largest stock and my capital is up 73% even after today's fall. Add in the dividends and it's done very well.
probably got lucky with the timing as the decade before would not have been so impressive - investors need to decide on the prospects for the next decade
that is about a 4 fold increase in about 10 years
''Have to treat mega pharma stocks as income stocks with limited capital growth but a decent dividend''
I first bought at about £30 - I don'y call that limited capital growth
Have to treat mega pharma stocks as income stocks with limited capital growth but a decent dividend…..even 10% gain from here is like creating a company worth 18bn….and remember these are really global stocks priced in USD not £ so it goes up and down with the exchange rate.
Growth can come through the new drug pipeline and taking risks in licensing /take it over early stage companies to boost growth. AZ has done well with its M&A and drug pipeline for the last 10 years but those drugs will start to exit patent protections in the next decade which will mean it has to run harder to maintain its earnings.
There are plenty of smaller companies that have potential to create a brilliant new treatment or be taken over and will be more volatile than AZ. If you want to play in these then avoid anything that has less than 2 years funding visibility - it could just vaporise before your eyes.
As well as a few specific pharma I hold L&G Global Healthcare & Pharmaceutical OEIC to give wider exposure to the market - it has done pretty well for me and is certainly less volatile than my individual stocks.